drugset / Trial / NCT01626209
A Phase I Study of BKM120 in Adult Chinese Patients With Advanced Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Dose escalation study with a dose expansion phase, to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of two dose levels of BKM120 when administered orally.
Timeline
- Start
- 2012-07
- Primary completion
- 2014-04
- Completion
- 2014-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Buparlisib | Small molecule | 80 mg | Oral |
| Subject | Buparlisib | Small molecule | 100 mg | Oral |